Ballesteros-Flores CG, Ballesteros-Rentería G, Terán-Flores H, Navarrete-Colin YA

Idioma: Español
Referencias bibliográficas: 30
Paginas: 54-57
Archivo PDF: 177.44 Kb.

RESUMEN

Introducción: El fibrinógeno, también llamado Factor I. Es una glicoproteina plasmática dimérica con propiedades globulares/fibrosas y de elevado peso molecular (340 kDa). En adultos sanos, la concentración plasmática se encuentra en rango de 2 a 4 g/L. Objetivo: Análisis bibliográfico sobre los principales aspectos bioquímicos del fibrinógeno en pacientes con trauma. Material y Métodos: Revisión de la literatura médica en idioma ingles durante el periodo 2022 a 2024. Se seleccionaron los artículos científicos más relevantes de fibrinógeno y trauma. Resultados: El fibrinógeno, se encuentra disminuido frecuentemente en pacientes que presentan un estado de choque hemorrágico. El nivel de fibrinógeno crítico es ≤ 1 g/L. De tal manera, se recomienda mantener un nivel de fibrinógeno plasmático ≥ 2 g/L. Conclusión: La presente revisión bibliográfica, demuestra que los pacientes con estado de choque hemorrágico, tendrán una disminución significativa del fibrinógeno plasmático.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Zhang Q, Zhou S, Zhou, J. Tigecycline Treatment Causes a Decreasein Fibrinogen Levels. Antimicrob. Agents Chemother. 2015;(59):1650-1655. DOI: 10.1128/AAC.04305-14.

2. Pavord S, Maybury H. How I Treat Postpartum Hemorrhage. Blood2015;(125) 2759-2770. DOI: 10.1182/ blood-2014-10-512608.

3. Inaba K, Karamanos E, Lustenberger T, et al. Impact of fibrinogenlevels on outcomes after acute injury in patients requiring a massivetransfusion. J Am Coll Surg. 2013;(216):290-7.

4. O’Shaughnessy F, Atterbury C, Bolton Maggs. et al. Guidelines forthe use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.Br J Haematol. 2004;(126):11-28.

5. Rourke C, Curry N, Khan S. et al. Fibrinogen Levels during TraumaHemorrhage, Response to Replacement Therapy, and Associationwith Patient Outcomes. J. Thromb. Haemost. 2022;(120):10-28.

6. Spahn R, Bouillon B, Cerny V. et al. Management of bleedingand coagulopathy following major trauma: an updated Europeanguideline. Crit Care. 2013;(17):76.

7. Cothren C, Moore E, Hedegaard B. et al. Epidemiology of urbantrauma deaths: a comprehensive reassessment 10 yeras later.World J Surg. 2007;(31):1507-11.

8. Moore Hb, Moore EE. Temporal changes in fibrinolysis followinginjury. Semin Thromb Hemost. 2020;(46):189-191.

9. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, WadaT, et al. Disseminated intravascular coagulation with a fibrinolyticphenotype at an early phase of trauma predicts mortality. ThrombRes. 2009;(124):608-13.

10. Moore Hb, Moore EE, Gonzalez E. et al. Hiperfibrinolysis, physiologicfribrinolysis, and fribrinolysis shutdowm: The spectrum ofpostinjury fribrinolysis and relevance to antifibrinolytic therapy. JTrauma Acute Care. 2014;(77):811-817.

11. Moore Hb, Moore EE, Liras IN. et al. Acute fribrinolysis shutdowmafter injury occurs frequently and increases mortality: A multicenterevaluation of 2,540 severely injured patients. J Am Coll Surg2016;(222):347-355.

12. Simmons JW, Powel MF. Acute traumatic coagulopathy: Pathophysiologyand resuscitation. Br J Anaesth. 2016;(117):31-43.

13. Hiippala ST, Myllyla GJ, Vhatera EM: Hemostatic factors and replacementof major blood loss with plasma-poorred cell concentrates.Anesth Analg. 1995;(81):360-365.

14. Champion HR, Bellamy RF, Roberts CP, et al. A profile of combatinjury. J Trauma 2003;54(5)(suppl):S9-S13.

15. Thomas D, Wee M, Clyburn P. et al. Association of Anaesthetistsof Great Britain and Ireland, Blood transfusion and the anaesthetist:management of massive haemorrhage. Anaesthesia.2010;(65):1153-1161.

16. Hayakawa M, Gando S, Ono Y, Wada T, Yanagida Y, SawamuraA. Fibrinogen level deteriorates before other routine coagulationparameters and massive transfusion in the early phase of severetrauma: a retrospective observational study. Semin Thromb Hemost.2015;(41):35-42.

17. Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation,fibrinolysis and inflammation. Thromb Haemost.2014;(112):649-658.

18. López M, Martinuzzo M, Fares T, et al. Tromboelastometría ytromboelastografia. Acta Bioquímica Clínica Latinoamericana.2016;(50):319-328.

19. McQuilten Z, Bailey M, Cameron, et al. Fibrinogen concentrationand use of fibrinogen supplementation with cryioprecipitate in patientswith critical bleeding receiving massive transfusión: A bi-nationalcohort study. Br J Haematol 2017;(179):131-141.

20. Task Force on Patient Blood Management for Adult Cardiac Surgeryof the European Association for Cardio-thoracic Surgery (EACTS)and the European Association of Cardiothoracic AnesthesiologyEACTA, Boer C, Meesters MI. et al. 2017 EACTS/EACTA Guidelineson patient blood management for adult cardiac surgery. Journalof Cardiothoracic and Vascular Anesthesia. 2018;(32):88-120.

21. Jensen H, Stensballe J, Afshari A. Comparing efficacy and safetyof fibrinogen concentrate to cryoprecipitate in bleeding patients:a systematic review. Acta Anaesthesiologica Scandinavica.2016;(60):1033-42.

22. Koji Y, Akihiko U and Junki T. Fibrinogen concéntrate administrationattributes to significant reductions of blood loss and transfusiónrequirements in thoracic aortic repair. Journal of CardiothoracicSurgery. 2014;9:90.

23. Taylor J, Cotton B. Problemas de coagulación en el paciente traumatizado.En: cameron J editor. Terapias quirúrgicas actuales.13ed. España; Elsevier. 2021:1251-1259.

24. James Winearls and colls. Fibrinon Early In Severe Trauma study(FEISTY) results from an Australian multicentre randomised controlledpilot trial. Critical care and resucitation. 2021:(23).

25. Cannon W. Hemorrhagic Shock. The New England Journal Of Medicine.2018;378(4):370-379.

26. Winearls J, Reade MC, McQuilten Z, et al. Fibrinogen in traumatichaemorrhage. Curr Opin Anaesthesiol 2021;(34):514–520.

27. Alexander J, Vlaar C, Sanne de Bruin, Marije Wijnberge S. JorindeRaasveld, et al. Transfusion strategies in bleeding critically ill adults:a clinical practice guideline from the European Society of IntensiveCare Medicine. Intensive Care Med. 2021;(47):1368-1392.

28. Schlimp C and Schochl H. The role of fibrinogen in trauma-inducedcoagulopathy. Hamostaseologie. 2014;34(1):29-39.

29. Ross J, Curry N, Cole E, et al. Effect or early empirical high-dosecryoprecipitate therapy on survival in major traumatic hemorrhage(CRYOSTAT-2);A randomized controlled trial. JAMA 2023.330(14):1315-1325.

30. Wikkelsoe A, J Afshari, A.,Stensballe et al. The FIB-PPH trial: Fibrinogenconcentrate as initial treatment for postpartum heamorrhage:study protocol for a randomized controlled trial. Trials.2012;(2):92-110.